What records are connected here?
- Evidence lanes
- 3
- Source years
- 18
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsCancer
Degarelix is a lab-made peptide that blocks the gonadotropin-releasing hormone (GnRH) receptor, and is the active ingredient in Firmagon.1,2 FDA approved Firmagon in 2008 for advanced prostate cancer. In its label’s trial it brought testosterone down faster than leuprolide, a GnRH agonist.1,2 In a randomized trial of 610 men described in the label, it kept testosterone at castration levels for a year about as often as leuprolide, and reached those levels faster.1
| What it is | A GnRH receptor antagonist: the label states that it binds reversibly to pituitary GnRH receptors, reducing release of the hormones that drive testosterone production.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Firmagon with an original approval date of December 24, 2008. The cited label has no boxed warning.1,2 |
| Human evidence | One open-label, randomized trial in 610 men with prostate cancer comparing degarelix with leuprolide for one year, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Degarelix is a synthetic peptide that blocks the receptor for gonadotropin-releasing hormone (GnRH) in the pituitary gland.1
In the United States it is the active ingredient of Firmagon, from Ferring Pharmaceuticals, according to Drugs@FDA.2
The label states that degarelix binds reversibly to pituitary GnRH receptors, reducing the release of gonadotropins and, in turn, testosterone, which many prostate cancers need to grow.1
In the label’s trial, 52% of men on degarelix had castration levels of testosterone on day 1 and 99% by day 7, compared with 0% and 1% on leuprolide.1
The label describes an open-label, multicenter, randomized trial (NCT00295750) in which 620 men with prostate cancer were randomized to one of two degarelix treatment arms or leuprolide for one year; 610 made up the trial population.1
From day 28 to day 364, the estimated rate of keeping testosterone at castration levels was 97.2% with degarelix as approved and 96.4% with leuprolide, according to the label.1
The label reports that antibodies to degarelix developed in 10% of patients after one year, with no indication that they affected efficacy or safety.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Firmagon, application NDA 022201, with an original approval date of December 24, 2008.2
The Firmagon label cited here (DailyMed SPL version 18, published February 1, 2024) states that it is indicated for treatment of patients with advanced prostate cancer.1
The label has no boxed warning. It is contraindicated in people with a history of severe allergic reactions to degarelix, and the label notes that long periods of medical castration can be expected to lower bone density.1
Whether faster suppression changes outcomes: the label’s trial measured testosterone as its main outcome, and the label states that no evidence has shown that a faster fall in PSA is related to a clinical benefit.1
Effects over many years, beyond the one-year trial and its extension study described in the label.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Degarelix: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Degarelix are a bounded selection, not every registration or paper about Degarelix. For the years before Degarelix was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Degarelix as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Degarelix in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Firmagon for advanced prostate cancer. A randomized trial of 610 men described in the label found that degarelix kept testosterone at castration levels for a year about as often as leuprolide. The trial measured hormone levels rather than survival.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Firmagon for advanced prostate cancer. A randomized trial of 610 men described in the label found that degarelix kept testosterone at castration levels for a year about as often as leuprolide. The trial measured hormone levels rather than survival.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 17, 2026
Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.↗Added to PeptideScanner November 17, 2026Literature metadata · added November 17, 2026
Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, 1H NMR, and FTIR Techniques.↗Source date November 17, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT03689699↗Source date October 15, 2026Literature metadata · added November 15, 2026
[Treatment of advanced hormone-sensitive prostate cancer using degarelix].↗Source date October 10, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
29 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
31 of 31 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00116753 at 2026-11-15T21:52:09.579Z. Its registry update date was 2010-12-10, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00116779 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-12-19, and PeptideScanner's reviewed identity mapping was degarelix.
31 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 24, 2008 to November 17, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 43041099 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2027-01 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03689699 at 2026-11-15T21:52:09.579Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was degarelix.↗
Literature metadata
PubMed lists PMID 34907463 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2021-12-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41918172 in Acta neuropsychiatrica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41970125 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-03-10 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38413843 in The Prostate as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-27 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24568188 in Journal of medical economics as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-02-25 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00117286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was degarelix.↗
Literature metadata
PubMed lists PMID 35923949 in Frontiers in public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-07-18 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03069937 at 2026-11-15T21:52:09.579Z. Its registry update date was 2025-10-15, and PeptideScanner's reviewed identity mapping was degarelix.↗
Literature metadata
PubMed lists PMID 20069136 in Drugs of today (Barcelona, Spain : 1998) as Journal Article, Review, with publication-date metadata of 2009-10 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 34350976 in The Cochrane database of systematic reviews as Journal Article, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2021-08-05 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026